Discounted Cash Flow (DCF) Analysis Levered

Aridis Pharmaceuticals, Inc. (ARDS)

$2.21

+0.01 (+0.45%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.862.768.8428.3390.83291.20933.532,992.729,594.1230,756.95
Revenue (%)
Operating Cash Flow -17.56-24.27-8.16-20.48-0-1,797.53-5,762.55-18,473.67-59,223.15-189,858.41
Operating Cash Flow (%)
Capital Expenditure -0.70-0.68-0.17-0.37-0-63.47-203.48-652.31-2,091.18-6,703.93
Capital Expenditure (%)
Free Cash Flow -18.26-24.95-8.33-20.84-0-1,861-5,966.03-19,125.98-61,314.33-196,562.35

Weighted Average Cost Of Capital

Share price $ 2.21
Beta 1.133
Diluted Shares Outstanding 9.17
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.132
Total Debt -
Total Equity 20.26
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 0.862.768.8428.3390.83291.20933.532,992.729,594.1230,756.95
Operating Cash Flow -17.56-24.27-8.16-20.48-0-1,797.53-5,762.55-18,473.67-59,223.15-189,858.41
Capital Expenditure -0.70-0.68-0.17-0.37-0-63.47-203.48-652.31-2,091.18-6,703.93
Free Cash Flow -18.26-24.95-8.33-20.84-0-1,861-5,966.03-19,125.98-61,314.33-196,562.35
WACC
PV LFCF ---0-----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -200,493.59
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -19.99
Equity Value -
Shares Outstanding 9.17
Equity Value Per Share -